Aims: Sorafenib, which has been used extensively for the treatment of renal cell cancer and obstruction (UUO) and further explored the potential mechanism. Methods: Mice underwent UUO followed by vehicle or sorafenib treatment. The expression of CD68, a macrophage using confocal microscopy. Results: Renal histopathology improved in the UUO-sorafenib decreased by sorafenib. Immunohistochemistry showed that CD68 and CXCR3 had a similar distribution, whereas MCP1 was observed predominantly in the tubular epithelial cells. Double CXCR3. It also revealed that CXCR3 interacted with CXCL11 in the UUO mouse kidneys. sorafenib mouse kidneys. Conclusions: Taken together, the results indicated that sorafenib mechanisms underlying the protective effects of sorafenib.
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